No Data
Nanjing Vishee Medical Technology Co., Ltd (688580.SH): Actively exploring the application scenarios of AI technology in biofeedback, brain function, rehabilitation robots, and the field of rehabilitation Indicators.
Gelonghui reported on March 13 that Nanjing Vishee Medical Technology Co., Ltd (688580.SH) stated on the investor interaction platform that the company's existing product designs have actively utilized intelligent technology to enhance the automation and intelligence level of products: for example: ① Transcranial Magnetic Stimulation Device (MagNeuro ONE series): introducing an AI-driven brain imaging processing system to achieve precise targeting and intelligent dosage adjustment, providing the most advanced transcranial magnetic technology for high-end clinical and scientific research; ② 3A RF Robot: combining high-precision graphic recognition algorithms with real-time temperature control technology to achieve automation of treatment pathways and visualization of the process, promoting the treatment.
Weiss Healthcare: Nanjing Weisi Medical Technology Co., Ltd. 2024 Annual Performance Report Announcement
Nanjing Weisi Medical Technology Co., Ltd. 2024 Annual Performance Report Announcement
Nanjing Vishee Medical Technology Co., Ltd (688580.SH): Net income of 0.1 billion yuan for the fiscal year 2024, a decrease of 26.61% year-on-year.
Gelonghui February 26丨Nanjing Vishee Medical Technology Co., Ltd (688580.SH) announced its performance report for the year 2024. During this reporting period, the company achieved total operating revenue of 0.4 billion yuan, a year-on-year decrease of 13.45%; the net income attributable to the parent company was 0.1 billion yuan, a year-on-year decrease of 26.61%; the net income attributable to the parent company after deducting non-recurring gains and losses was 83.8046 million yuan, a year-on-year decrease of 31.15%. During this reporting period, faced with challenges such as relatively insufficient market demand and intensified competition, the company's overall operation performance showed slight fluctuations. The company has long adhered to focusing on the cornerstone rehabilitation business and expanding into emerging areas such as medical aesthetics.
Market Might Still Lack Some Conviction On Nanjing Vishee Medical Technology Co., Ltd (SHSE:688580) Even After 28% Share Price Boost
Nanjing Vishee Medical Technology Co., Ltd (SHSE:688580) CEO Zhiyu Wang, the Company's Largest Shareholder Sees 12% Reduction in Holdings Value
Nanjing Vishee Medical Technology Co., Ltd's (SHSE:688580) 26% Dip In Price Shows Sentiment Is Matching Earnings